NVP-TAE 226
Catalog No. A11507
NVP-TAE 226是一种强效FAK抑制剂,IC50为5.5 nM,对pyk2(IC50=3.5 nM)有适度的强效作用;对InsR, IGF-1R, ALK和c-Met的效力降低10-100倍。
Catalog Num | A11507 |
---|---|
M. Wt | 468.94 |
Formula | C23H25ClN6O3 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 761437-28-9 |
Synonyms | TAE226, TAE 226 |
SMILES | CNC(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCOCC4)OC |
NVP-TAE 226是一种强效FAK抑制剂,IC50为5.5 nM,对pyk2(IC50=3.5 nM)有适度的强效作用;对InsR, IGF-1R, ALK和c-Met的效力降低10-100倍。
Targets
Target | Value |
---|---|
PYK2 | IC50: 3.5nM |
FAK | IC50: 5.5nM |
Insulin Receptor | IC50: 43.5nM |
IGF-1R | IC50: 140nM |
c-Met | IC50: 160nM |
FLT4 | IC50: 220nM |
KDR | IC50: 360nM |
FLT3 | IC50: 480nM |
CDK1/CyclinB | IC50: 540nM |
Tek | IC50: 580nM |
FGFR3(K650E) | IC50: 630nM |
FGFR1 | IC50: 750nM |
JAK2 | IC50: 840nM |
c-Src | IC50: 905nM |
HER2 | IC50: 945nM |
RET | IC50: 1.3μM |
HER1 | IC50: 1.7μM |
RET(M918T) | IC50: 2.3μM |
PDK-1 | IC50: 2.4μM |
PDGFRβ | IC50: 2.6μM |
FLT1 | IC50: 3.4μM |
c-Abl | IC50: 5.85μM |
ZAP70 | IC50: 7.7μM |
Syk | IC50: 7.9μM |
PKA | IC50: >10μM |
PKB | IC50: >10μM |
C-Raf | IC50: >10μM |
In vitro (25°C) | DMSO | 93 mg/mL (198.32 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 0.5% methylcellulose | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 21.32 mL | 106.62 mL | 213.25 mL |
0.5 mM | 4.26 mL | 21.32 mL | 42.65 mL |
1 mM | 2.13 mL | 10.66 mL | 21.32 mL |
5 mM | 0.43 mL | 2.13 mL | 4.26 mL |
*The above data is based on the productmolecular weight 468.94. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.